



COLORADO

Department of Health Care
Policy & Financing

AGENDA

Pharmaceuticals & Therapeutics Committee

Department of Health Care Policy & Financing

Zoom Webinar Registration: TBA
Tuesday, January 07, 2025, 1:00-5:00 P.M.

1. Committee Member Introductions

Introduction of New Members

Vote for Committee Positions - Chairperson, Vice Chairperson

2. Unfinished Business and General Orders

Approval of minutes from October 8, 2024 P&T meeting

Updates from October 8, 2024 P&T Meeting

3. New Business

Updates from the Prior Authorization Call Center

4. Drug Classes Up for Review

Review of Opioids - Short-Acting, Long-Acting

Review of Anticonvulsants, Oral

Review of Anti-Parkinson's Agents

Review of Atypical Antipsychotics - Oral/Topical

Review of Stimulants and Related Agents

Mass review drug classes:

- Non-Opioid Analgesia Agents - Oral & Topical
- Opioids, Fentanyl Preparations
- Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) - Oral & Non-Oral
- Newer Generation Antidepressants
- Monoamine Oxidase Inhibitors (MAOIs)
- Tricyclic Antidepressants (TCAs)
- Benzodiazepines (Non-Sedative Hypnotic)
- Anxiolytics, Non-Benzodiazepine
- Calcitonin Gene-Related Peptide Inhibitors (CGRPIs)
- Lithium Agents
- Neurocognitive Disorder Agents
- Sedative Hypnotics
- Skeletal Muscle Relaxants



- Triptans, Ditans and Other Migraine Treatments - Oral & Non-Oral
- Multiple Sclerosis Therapies - Disease Modifying & Symptom Management
- Ophthalmics, Allergy
- Ophthalmics, Immunomodulators
- Ophthalmics, Anti-Inflammatories
- Ophthalmics, Glaucoma

Each Review will contain:

- Oral presentation by manufacturers, providers, and public
- Overview for each Drug Class, including market share overview
- Committee Discussion and Recommendations for each Class

Mass Review drug classes will only include:

- Overview for each Drug Class, including market share overview

Presentations:

- Interested parties who want to present at the meeting shall give advanced notice and provide a one-page summary of the clinical testimony that will be presented for P&T Committee dissemination.
- Advance notice requests to present and/or written public comments can be submitted to Jessica Czechowski, Director - Clinical Account Services, Jessica.Czechowski@primetherapeutics.com and carbon copy: Greg Miller, PDL & Clinical Strategy Pharmacist, greg.l.miller@state.co.us. Once approved, public comments will be distributed to P&T Committee Members.
- Requests and public comment summaries are due by **December 31, 2024 by 5pm MST**.

5. Adjourn

Upcoming Meeting Date: April 8, 2025.

Reasonable accommodations will be provided upon request. Auxiliary aids and services for individuals with disabilities and language services for individuals whose first language is not English may be provided upon request. Please notify the [504/ADA Coordinator](#) or hcpf504ada@state.co.us at least one week prior to the meeting to make arrangements.

